The Growing IRB Bottleneck in Low-Risk Research

Institutional Review Boards were created to protect human subjects. Their role is foundational to ethical research in the United States, notably under the federal regulations known as the Common Rule (45 CFR 46).

 

A less visible challenge has emerged across healthcare systems, universities, and applied research settings: increasing bottlenecks in the review of low-risk and quality improvement studies.

 

According to the U.S. Department of Health and Human Services, research that involves minimal risk may qualify for Exempt status under specific categories outlined in 45 CFR 46.104. In parallel, many quality improvement initiatives may not meet the regulatory definition of “research” at all if they are designed for internal operational enhancement rather than generalizable knowledge.

 

In practice, determining the appropriate regulatory pathway is often complex.

 

Multiple studies have documented prolonged IRB timelines. Research published in Academic Medicine and the Journal of Empirical Research on Human Research Ethics has found that review timelines can vary dramatically across institutions, sometimes extending for months, even for minimal-risk protocols.

 

When classification is uncertain, institutions frequently default to full board review. This approach is rational, as escalation reduces perceived regulatory risk.

 

This pattern produces secondary effects that are directly reflected in institutional key performance indicators (KPIs):

• Administrative congestion within IRBs, which can be tracked by average review duration and volume

• Delays in quality improvement implementation, reflected in increased QI cycle time

• Increased institutional costs, often measured as cost per review

• Researcher frustration and withdrawal, which may contribute to staff turnover or reduced project completion rates

 

In large health systems, where rapid-cycle quality improvement is central to performance metrics and patient safety initiatives, these delays can materially affect operations.

 

The distinction between “research” and “quality improvement” has been a topic of debate for years. The Office for Human Research Protections has issued guidance clarifying that activities formulated solely for internal improvement, without intent to contribute to generalizable knowledge, may fall outside the definition of human subjects research.

Nevertheless, intent, study design, publication plans, and methodology often blur the distinction. A single clarifying question, such as “Will data leave the institution?” can assist in framing the decision. In practice, a straightforward decision tree that considers project intent, study methodology, and dissemination of results can serve as an initial guide for institutions seeking clarity. For a deeper look at navigating these pathways, see our guide to choosing the right IRB path for your study.

 

As healthcare delivery models become increasingly data-driven and implementation science expands, a greater number of projects fall into this regulatory gray area.

 

This situation does not represent a failure of ethical standards but rather a challenge in regulatory classification.

 

Healthcare organizations are increasingly evaluated based on innovation, outcomes, and evidence generation. However, the regulatory infrastructure for oversight has not consistently evolved in parallel with operational research models.

 

This tension raises a legitimate policy question:

 

How can institutions maintain rigorous ethical standards while minimizing unnecessary barriers for minimal-risk research?

 

The solution is not deregulation but rather increased clarity.

 

Clarity regarding definitions.Clarity regarding regulatory pathways.

Clarity is provided early in the project lifecycle.

 

Ethical review is not optional. It is essential.

 

Efficiency in minimal-risk and exempt determinations may represent the next frontier in research administration reform.

 

With the emergence of digital platforms, standardized decision frameworks, and federally aligned tools, institutions have new opportunities to reduce review timelines without compromising compliance.

 

In an era when healthcare organizations are expected to improve outcomes in real time, the ability to rapidly determine the appropriate regulatory pathway may constitute not only an administrative improvement but also a strategic advantage.

 

Ethics must remain uncompromised.

 

Unnecessary delay should not be equated with rigor.

 

Closing the Classification Gap